Drug intelligence / Profile preview

LYSG-191

Development stage: Preclinical
Lead developer: Lysigen Biotechnology
Modality: Recombinant Proteins and Enzymes
Administration: Topical

Overview

LYSG-191 (StaphLyride) is a preclinical-stage bacteriophage-derived lysin enzyme being developed by Lysigen Biotechnology for the treatment of atopic dermatitis and eczema. The drug specifically targets *Staphylococcus aureus*, a pathogen that frequently colonizes the skin of patients with atopic dermatitis and contributes to inflammation and disease flares. LYSG-191 functions by enzymatically degrading the peptidoglycan layer of the *S. aureus* cell wall, resulting in rapid bacterial lysis. This targeted biologic approach aims to restore the skin microbiome balance and alleviate inflammatory symptoms without the use of traditional antibiotics, potentially avoiding the development of antimicrobial resistance.

Other names: StaphLyride

Targets

PGN (Peptidoglycan)

Beyond the preview

Go deeper on LYSG-191.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LYSG-191.

Explore the full profile